Celecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip

NCT00174317

Last updated date
Study Location
Pfizer Investigational Site
Aston Clinton, Bucks, GP22 5LB, United Kingdom
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hip Osteoarthritis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
45 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosed with osteoarthritis of hip and requiring joint replacement

- Eligible for chronic therapy with an NSAID

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Hip surgery anticipated within 8 calendar weeks after first visit


- Active gastrointestinal disease or recent diagnosis of gastrointestinal ulceration
(within 60 days of first visit)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Hip OsteoarthritisCelecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip
NCT00174317
  1. Aston Clinton, Bucks
  2. Ely, Cambs
  3. St. Austell, Cornwall
  4. Lancaster, England
  5. Sheffield, England
  6. Newport, Gwent
  7. Chingford, London
  8. Harrow, Middlesex
  9. Greenisland, Carrickfergus, Northern Ireland
  10. Oxford, Oxon
  11. Greenock, Renfrewshire
  12. Barry, South Glamorgan
  13. Barnsley, South Yorkshire
  14. Ashford, Surrey
  15. Newcastle-Upon-Tyne, Tyne & Wear
  16. Trowbridge, Wiltshire
  17. Aberdeen,
  18. Amersham,
  19. Bath,
  20. Bath,
  21. Belfast,
  22. Bradford,
  23. Cardiff,
  24. Carshalton,
  25. Chertsey,
  26. Edinburgh,
  27. Glasgow,
  28. Lancaster,
  29. Leystonstone, London,
  30. Liverpool,
  31. Liverpool,
  32. London,
  33. Manchester,
  34. Northampton,
  35. Norwich,
  36. Nuneaton,
  37. Peterborough,
  38. Sheffield,
  39. Southampton,
  40. Truro,
  41. Wansford,
  42. Watford,
  43. Westbury,
  44. Wigan,
ALL GENDERS
45 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Celecoxib Versus Diclofenac In The Treatment Of Osteoarthritis Of The Hip
Official Title  ICMJE Clinical Protocol For A Multicentre, Double-Blind, Randomised, Parallel Group Study To Compare The Efficacy and Tolerability Of Celecoxib Vs. Diclofenac In The Treatment Of Subjects With Osteoarthritis Of The Hip Requiring Joint Replacement Therapy
Brief Summary To determine if celecoxib 200 mg once daily is as effective as diclofenac 50 mg three times daily in the treatment of pain symptoms associated with osteoarthritis of the hip
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Condition  ICMJE Osteoarthritis, Hip
Intervention  ICMJE
  • Drug: Celecoxib
  • Drug: Diclofenac
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: September 9, 2005)
250
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE February 2005
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosed with osteoarthritis of hip and requiring joint replacement
  • Eligible for chronic therapy with an NSAID

Exclusion Criteria:

  • Hip surgery anticipated within 8 calendar weeks after first visit
  • Active gastrointestinal disease or recent diagnosis of gastrointestinal ulceration (within 60 days of first visit)
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 45 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00174317
Other Study ID Numbers  ICMJE COXA-0508-261
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date December 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP